BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

NiedlFree Technologies revolutionises diabetes treatment by replacing injections with sprays

03 November 2023 | News

Offering a convenient alternative for patients once "Ozulin" hits the market in 2025-26



Hyderabad-based NiedlFree Technologies, founded just two years ago, is set to transform the world of medical injectables, including treatments for Diabetes, Cancer, Osteoporosis, Alzheimer's, and more. Their groundbreaking innovation converts injectable medications into simple nasal or oral sprays, eliminating the need for painful injections.

During a press conference at the Taj Deccan, Dr K Koteswara Rao, CA Viswanath Toshniwal, and Dr Jeetendra Ambulge, all directors of NiedlFree Technologies, unveiled this revolutionary drug delivery system. This technology was initiated by Transgene Biotek nearly two decades ago and is now being advanced by NiedlFree, bringing it closer to reality.

NiedlFree has achieved painless and convenient drug administration, particularly with insulin for diabetes, which can now be delivered as an oral or nasal spray. Results from a recent study conducted by Palamur Biosciences in dogs demonstrated a bioavailability of over 90%, far surpassing any other company's injectable methods. This advancement has the potential to revolutionise global diabetes treatment, offering a convenient alternative for patients once "Ozulin" hits the market in 2025-26.

Giving more insights, the directors of the NiedlFree Tech company revealed that the drug delivery medical technology is not limited to diabetes; it holds promise for various medical conditions, including Alzheimer's, Parkinson's, and Cancer, where hospital admissions for IV treatments can be replaced by simple and convenient oral sprays.

Moreover, NiedlFree is exploring partnerships with companies in the US and Europe to introduce their novel insulin product to the pet care market in 2024-25, paving the way for its eventual introduction in human diabetic markets worldwide. The impact of this technology is poised to be significant, offering a more comfortable and compliant approach to medical treatment for numerous conditions.